Data Support Fixed-Treatment Duration of Imbruvica/Venclexta Combo Could Lead to Treatment Discontinuation in Certain Patients With CLL/SLL

December 5th 2020, 9:07pm

By Ryan McDonald

Data suggest that patients with CLL/SLL who achieve confirmed undetectable minimal residual disease following 12 cycles of Imbruvica combined with Venclexta could possibly discontinue and reasonably remain off treatment.

High-Dose Imetelstat Could Offer Patients with High-Risk Myelofibrosis Improved Overall Survival

December 5th 2020, 8:00pm

By Jessica Skarzynski

An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial.

How Cold Weather Affects Patients with Cancer

December 5th 2020, 7:00pm

By Tampa Bay Radiation Oncology

Winter brings added challenges for patients with cancer. Here's what you need to know to take into consideration as the weather gets colder.

CURE®’s 8th Annual MPN Heroes Program Honors ‘Team of Warriors’ Who Have Overcome Challenges in Myeloproliferative Neoplasms

December 5th 2020, 3:00pm

By Ryan McDonald

Five patient advocates, two oncologists and one caregiver were honored during CURE®’s eighth annual MPN Heroes Program.

Sponsored by Kyowa Kirin: Understanding the Ins and Outs of CTCL

December 5th 2020, 1:00pm

Dr. Yuliya Linhares discusses cutaneous T-cell lymphoma and the role of a multidisciplinary team of specialists in designing and managing care.

Venclexta With Velcade and Dexamethasone May Improve Progression-Free Survival in Relapsed or Refractory Multiple Myeloma

December 4th 2020, 10:00pm

By Darlene Dobkowski, MA

The phase 3 trial found that this treatment improves progression-free survival (PFS) during 18.7 months of follow-up, although patients treated with Venclexta (venetoclax) a had increased mortality rates compared with those treated with placebo.

Faith, Science, and Miracles: A Conversation About CAR-T Cell Therapy with the Whitehead Family

December 4th 2020, 8:00pm

By Jessica Skarzynski

Emily Whitehead was the first child to receive chimeric antigen receptor (CAR)-T cell therapy. Eight years later, she and her parents discuss her ongoing remission from acute lymphoblastic leukemia.

Cancer, Boundaries, Safety and COVID-19 Considerations During the Holidays

December 4th 2020, 5:00pm

By Tamera Anderson-Hanna

Figuring out boundaries and safety in relation to COVID-19 has been an ongoing challenge this year, and with the holidays coming up pressure is mounting. Here is how one cancer survivor considered their boundaries this year.

Friday Frontline: Preliminary Evidence Shows Connection Between Cancer Recurrence and Stress-Related Hormones, Texas Mayor Tests Positive for COVID-19 After Cancer Diagnosis, and More

December 4th 2020, 4:00pm

By Conor Killmurray

From a recently published study showing preliminary connections between elevated levels of stress-related hormones and cancer recurrence, to a Texas mayor receiving a diagnosis of cancer and COVID-19, here’s what’s happening in the cancer landscape this week.

Evolving Standards and Heated Debates in the Treatment of Newly Diagnosed Multiple Myeloma

December 4th 2020, 2:00pm

Evolving standards of care in newly diagnosed multiple myeloma (MM) have given patients a wider variety of possibilities but can also be disconcerting. In a presentation during CURE®’s Educated Patient® Multiple Myeloma Summit, Dr. Clifton Mo, of Dana-Farber Cancer Institute, explores the treatment landscape and breaks down what these different options can offer patients.